Trial Profile

A Randomised, Placebo-controlled, Multicentre Phase IIb Study Evaluating the Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Apr 2025 According to a IRLAB Therapeutics media release, company will present cross-sectional analysis of baseline data from the trial, focussing on interrelations between different phenotypic traits in this population at the AD/PDTM 2025: 19th International Conference on Alzheimer and Parkinson Diseases and related neurological disorders, taking place in Vienna, Austria, April 1-5, 2025.
28 Mar 2025 Results presented in the IRLAB Therapeutics Media Release.
05 Mar 2025 According to a IRLAB Therapeutics media release, the company will host a live webcast in connection with announcing the topline results from the Phase IIb study on March 5, 2025, at 15:30 CET.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com